# Biophta

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/biophta

- Industry: Pharmaceuticals
- Headquarters: Paris, France
- Website: www.biophta.com
- Total disclosed funding: $7M
- Latest round: Seed (Jun 3, 2024)
- Investors on record: 5

## About

Based in Paris, France, and founded in 2020 by co-founders Jean Cuine and Jean Garrec, Bioadhesive Ophthalmics doing business as Biophta, operates as a preclinical biotech company producing eye care products for the healthcare industry. In June 2024, Biophta raised EUR 6.5 million in seed funding co-led by UI Investissement, Elaia Partners, and GO Capital, with participation from Unither Pharmaceuticals.

Biophta provides a variety of topical therapies such as eye drops, gels, ointments, and many more for treating the front-of-the-eye. The company focuses on retinal diseases and treating the back-of-the-eye, that require intra-ocular injections and absorption rate of eye drops. In addition, the firm’s technology that is based on thiomer biopolymers, offers a care for conditions like glaucoma, macular edema, and other chronic eye diseases. 

The company plans to use the funding from June 2024 to accelerate first-in-human trial of topical ophthalmic inserts in the treatment of glaucoma and to advance a second program in macular edema, thus targeting the two leading causes of blindness.

## Funding rounds

- Seed, Jun 3, 2024, $7M — Elaia Partners, GO Capital, UI Investissement, Unither Pharmaceuticals, HTL S.A.S.

## Investors

- Elaia Partners (https://capitalatlas.ai/funds/elaia-partners) — Seed
- GO Capital — Seed
- UI Investissement (https://capitalatlas.ai/funds/ui-investissement) — Seed
- Unither Pharmaceuticals — Seed
- HTL S.A.S. — Seed